• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Samsung Gets FDA Nod for Versatile V7 Ultrasound System


Offering uniform high-resolution images through a combination of beamforming and enhanced image processing, the new ultrasound platform reportedly has an array of diagnostic features ranging from cardiovascular applications to breast lesion assessment.

The Food and Drug Administration (FDA) has granted 510(k) clearance to the V7 Ultrasound system, which provides enhanced, high-resolution imaging for a variety of clinical applications Including cardiovascular and breast imaging, according to Samsung, the manufacturer of the device.

Samsung noted the increased resolution and clarity of imaging with the V7 Ultrasound system stems from Crystal Architecture, which includes the use of S-Vue Single Crystal Transducers and proprietary beamforming (CrystalBeam™) and image processing technologies (CrystalLive).

The ultrasound platform has a variety of specialized clinical features including the artificial intelligence (AI)-enabled UterineAssist, which provides automated measurements of the uterus; 2D Follicle, which allows automated measurements of follicles for gynecologic exams; and S-Detectfor Breast, which assesses breast lesions and applies appropriate BI-RADS ATLAS info to reporting.

“There is a continued demand on imaging professionals to deliver high-quality results in an efficient amount of time without compromising patient care,” noted David Legg, vice president and head of Boston Imaging, the United States headquarters for Samsung’s digital radiography and ultrasound business. “We’re proud to help address this by supplying one more solution that helps make clinical assessments effortless and treatment precise.”

Other clinical measurement tools with the V7 Ultrasound include ArterialAnalysis, which detects functional blood vessel changes; AutoIMT+, which measures the intima-media thickness of the posterior and anterior walls of the common carotid; and AutoEF, which assesses potential ejection fraction through different measurements in the left ventricle, according to Samsung.

Samsung said the V7 Ultrasound device also enables clinicians to get better image quality through technologies such as HQ-Visionand ClearVision. The company explained that HQ-Vision reportedly mitigates contributing characteristics to blurry imaging and ClearVision reduces noise with enhanced edge contrast of two-dimensional images.

Related Videos
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Expediting the Management of Incidental Pulmonary Emboli on CT
Radiology Challenges with Breast Cancer Screening in Women with Breast Implants
Related Content
© 2024 MJH Life Sciences

All rights reserved.